These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21094905)

  • 1. Central GLP-1 actions on energy metabolism.
    Velásquez DA; Beiroa D; Vázquez MJ; Romero A; López M; Diéguez C; Nogueiras R
    Vitam Horm; 2010; 84():303-17. PubMed ID: 21094905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
    Baggio LL; Drucker DJ
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of incretin hormones.
    Drucker DJ
    Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ways in which GLP-1 can regulate glucose homeostasis.
    D'Alessio DA; Sandoval DA; Seeley RJ
    J Clin Invest; 2005 Dec; 115(12):3406-8. PubMed ID: 16322789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1, glucose homeostasis and diabetes.
    Holst JJ; Deacon CF; Vilsbøll T; Krarup T; Madsbad S
    Trends Mol Med; 2008 Apr; 14(4):161-8. PubMed ID: 18353723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
    Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
    Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.
    Nakade Y; Tsukamoto K; Pappas TN; Takahashi T
    Brain Res; 2006 Sep; 1111(1):117-21. PubMed ID: 16884700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
    J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the treatment of type 1 diabetes mellitus.
    Haak T
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 3():S108-13. PubMed ID: 10522818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 and the brain: central actions-central sources?
    Trapp S; Hisadome K
    Auton Neurosci; 2011 Apr; 161(1-2):14-9. PubMed ID: 20951098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
    List JF; Habener JF
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E875-81. PubMed ID: 15140754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.